Why the study?
Diabetes mellitus type 2 significantly increases cardiovascular morbidity and mortality, prompting evaluation of novel anthropometric indices and adipocytokines to assess cardiovascular risk in these patients.
Do adipocytokines and novel anthropometric indices correlate with the 10-year risk of coronary heart disease in patients with type 2 diabetes mellitus?
Do adipocytokines and novel anthropometric indices correlate with the 10-year risk of coronary heart disease in patients with type 2 diabetes mellitus?
Answers are grounded in this paper and cite their sources.
Adiponectin, the Adiponectin/Resistin index, and the abdominal volume index (AVI) may serve as useful surrogate markers for evaluating cardiovascular risk in patients with type 2 diabetes.
INTRODUCTION: Diabetes mellitus type 2 (T2DM) significantly increase the risk of cardiovascular (CV) disease morbidity and mortality. This study aimed to evaluate the potential of some novel anthropometric indices and adipocytokines to evaluate CV risk among T2DM patients. METHODS: A total of 112 patients (men, 57; women, 55) with T2DM visiting Family Medicine and Endocrine counseling in the area of Health centers of Sarajevo Canton were included in this study. The sera samples were analyzed for fasting blood glucose (FBG), HbA1c, lipid profile parameters, adiponectin, and resistin levels. The Adiponectin/Resistin Index (A/R Index) was estimated using the formula. The novel anthropometric measurements, including the Conicity index (CI), Lipid Accumulation Product (LAP), visceral adiposity index (VAI), abdominal volume index (AVI), and Body adiposity index (BAI) were estimated. The 10-year risk for coronary heart disease (CHD) and fatal coronary heart disease (fCHD) is calculated by using UKPDS Risk software. RESULTS: The adiponectin was shown as a statistically significant negative association with CHD in female subjects, and the A/R index as a statistically significant association with CHD and fCHD in male subjects. The AVI is superior to the CI, LAP, VAI, and BAI in assessing cardiometabolic risk in T2DM patients. CONCLUSIONS: Our study indicated that measuring adiponectin and A/R index, together with measuring AVI as a measure of general volume, can be used as surrogates in the evaluation of high cardiovascular risk among T2DM patients.
No takes yet. Share an insight, caveat, or question.
Fajkić et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: